This study sought to determine the role of the transcription factor E2F1 in CXCR4-mediated neurotoxicity and HIV neuropathology. We studied the effect of the HIV envelope protein gp120 on the expression of E2F1-dependent apoptotic proteins in human and rodent neurons and examined the expression pattern of E2F1 in the brain of HIVinfected individuals. Our findings suggest that in cultured neurons gp120 increased E2F1 levels in the nucleus, stimulated its transcriptional activity and enhanced the expression of the E2F1 target proteins Cdc2 and Puma. Studies with neuronal cultures from E2F1 deficient mice demonstrated that the transcription factor is required for gp120-induced neurotoxicity and up-regulation of Cdc2 and Puma. Levels of E2F1 protein were greater in the nucleus of neurons in brains of HIVinfected patients exhibiting dementia when compared to HIV-negative subjects or HIV-positive neurologically normal patients. Overall, these studies indicate that E2F1 is primarily involved in CXCR4-mediated neurotoxicity and HIV neuropathogenesis.
Introduction
The chemokine receptor CXCR4 is virtually ubiquitous and plays important roles in many physiological processes, such as neuronal migration, survival and differentiation; this receptor has also been implicated in the pathogenesis of cancer and AIDSincluding NeuroAIDS (Tran and Miller, 2003) . Analogous to other inflammatory disorders, neuronal injury and death are often found in AIDS patients (Adle-Biassette et al., 1995; Petito and Roberts, 1995; Shi et al., 1996) . Cellular alterations not necessarily associated to cell loss, such as dendritic pruning and synaptic impairment, are also thought to contribute to NeuroAIDS (Bellizzi et al., 2005; Everall et al., 1999; Sa et al., 2004) . Although highly active antiretroviral therapy (HAART) has greatly reduced HIV mortality and morbidity, the neurological complications of HIV infection significantly affect the clinical management of treated patients, and HIV-dementia still represents a serious concern for patients that have limited access to therapy (reviewed in GonzalezScarano and Martin-Garcia, 2005; McArthur et al., 2003) . As neurons are not the primary targets of HIV in the brain -the virus mostly infects macrophages and microglia and, to a lesser extent, astroglia -the neuropathogenesis of AIDS is not completely understood. A number of viral and cellular factors produced by infected or activated cells over a long period of time appear to be responsible for the neuronal damage caused by HIV (recent reviews: Gartner and Liu, 2002; Gonzalez-Scarano and MartinGarcia, 2005; Jones and Power, 2006; Mattson et al., 2005) . One of these factors is the HIV envelope protein gp120 that binds to chemokine receptors (i.e., CCR5 and CXCR4) on the surface of target cells, including neurons (Gartner and Liu, 2002; GonzalezScarano and Martin-Garcia, 2005; Hesselgesser et al., 1998; Jones and Power, 2006; Mattson et al., 2005) . Several in vitro and in vivo studies have shown the neurotoxic potential of the envelope protein and the involvement of chemokine receptors in this process (Gartner and Liu, 2002; Gonzalez-Scarano and Martin-Garcia, 2005; Jones and Power, 2006; Mattson et al., 2005) . The interaction of the co-receptors with the viral protein only partially resembles the interaction with their natural ligands (Farzan et al., 2002) , suggesting that activation of chemokine receptors may lead to cell death. Indeed, both apoptotic and pro-survival actions of chemokines have been reported (Cartier et al., 2005; Hesselgesser et al., 1998; Kaul and Lipton, 1999; Meucci et al., 1998) . Thus, chemokine receptors may mediate both survival and apoptotic pathways in neurons.
Brain-derived viruses generally use CCR5 for entry (Gonzalez-Scarano and Martin-Garcia, 2005) 
